immunology-congress-2018-scientifictracks

Page 24

Notes:

allied

academies

Journal of Timely Topics in Clinical Immunology | Volume 2

July 26-28, 2018 | Moscow, Russia

Immunology

Annual Congress on

High CD8 cell percentage and HCV control in HIV-1 controllers and HTLV-2 coinfected patients

Alejandro Vallejo

Ramón y Cajal University Hospital, Spain

atural control of HIV-1 infection occurs in less than 1% of

patients, maintaining very low plasma HIV-1 RNA loads or

even below the limit of detection, and usually with no clinical

signs of disease progression for many years without any

antiretroviral treatment.

HTLV-2/HIV-1co-infection is foundwith relativelyhigh frequency

among injection drug users in North America and Western

Europe. These patients have been reported to have lower levels

of plasma HIV-1 RNA loads before antiretroviral treatment, and

slower decrease of CD4 T cell counts.

These two groups of patients show an immune capacity that

enables a certain control of viral infections, dramatic control of

HIV-1 replication in the case of controllers. The aim of this study

was to compare viral and immunologic parameters between

HIV-1 controllers (N=75), HTLV-2/HIV-1 chronic progressors

(N=57), and HIV-1 chronic progressors (N=182).

Speaker Biography

Alejandro Vallejo is a biologist and completed his PhD at Complutense University,

Madrid, Spain. One of his fields of research is the study of immune parameters of HTLV

infections among HIV-1 infected patients. He moved to the Laboratory of Molecular

Virology, CBER, Food and Drug Administration, Bethesda, MD, USA, as a Post-Doctoral

Fellow (1995-2000) and developed several works on molecular epidemiology of HTLV

and HIV, and viral tropism. Then he joined the Immunovirology Laboratory at the Virgen

del Rocío University Hospital, Seville, Spain, as an independent researcher (2000-2008).

He focused his research on immune recovery of HIV-1-infected patients. Then he

moved to Ramon y Cajal University Hospital in Madrid to follow his research on HIV-1

immunopathology and continuing the research on HTLV-1/2 infections (2008) running

the Laboratory of Molecular Virology within the Infectious Diseases Department.